Matthew Moisan
Overview
Matthew Moisan is a co-lead of the Emerging Companies and Venture Capital practice and a resident in the firm's New York City office. He represents ECVC clients in structuring, formation, growth, and exits while providing practical, effective, business-minded counsel based on a keen awareness of the entrepreneurial lifecycle. Matthew has a unique way of deciphering his clients’ goals and an ability to turn complex legal issues into actionable business items. While his representation often begins when a company is merely an idea on the back of a napkin, he is also frequently engaged when the stakes are the highest: negotiating the sale of the business.
Career & Education
- Boston University, B.A., 2005
- Touro College Jacob D. Fuchsberg Law Center, J.D., 2008
- New York
Matthew's Insights
Event | 05.21.25
HealthTech Growth and Exit Strategy Summit
As a founder who has built a thriving HealthTech company, you understand the value of strategic foresight. Whether you're exploring acquisition opportunities, considering a merger, planning a recapitalization, or contemplating a sale, your next move demands careful orchestration to maximize business value and optimize personal outcomes.
Client Alert | 5 min read | 03.26.25
Client Alert | 3 min read | 03.17.25
SEC Issues No-Action Letter Clarifying Accredited Investor Verification Under Rule 506(c)
Insights
New York Smart Business Dealmakers Conference
|06.06.24
Crowell & Moring and The Ember Company Present: The FIRESIDE
|05.29.24
- |
02.11.22
The Wall Street Journal
Matthew's Insights
Event | 05.21.25
HealthTech Growth and Exit Strategy Summit
As a founder who has built a thriving HealthTech company, you understand the value of strategic foresight. Whether you're exploring acquisition opportunities, considering a merger, planning a recapitalization, or contemplating a sale, your next move demands careful orchestration to maximize business value and optimize personal outcomes.
Client Alert | 5 min read | 03.26.25
Client Alert | 3 min read | 03.17.25
SEC Issues No-Action Letter Clarifying Accredited Investor Verification Under Rule 506(c)